We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cobra Signs Agreement with Cequent to Evaluate Cobra's ORT Technology for RNAi Delivery
News

Cobra Signs Agreement with Cequent to Evaluate Cobra's ORT Technology for RNAi Delivery

Cobra Signs Agreement with Cequent to Evaluate Cobra's ORT Technology for RNAi Delivery
News

Cobra Signs Agreement with Cequent to Evaluate Cobra's ORT Technology for RNAi Delivery

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cobra Signs Agreement with Cequent to Evaluate Cobra's ORT Technology for RNAi Delivery"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

UK based Cobra Biomanufacturing Plc has signed an agreement with Cambridge, MA based Cequent Pharmaceuticals, Inc. to develop a treatment for, an inherited form of bowel tumour, Familial Adenomatous Polyposis (FAP).

The treatment will incorporate Cobra's proprietary antibiotic free maintenance technology (ORT) in conjunction with Cequent's proprietary TransKingdom RNA interference (tkRNAi) technology.

Commenting on the contract, David Thatcher, CEO at Cobra, said: "We are delighted to work with Cequent on this exciting project. Interference RNA (RNAi) has great potential for medicine, and Cequent's tkRNAi technology clearly represents an important breakthrough for the difficult, but exciting field of RNAi delivery. We believe the combination of Cobra's ORT technology with Cequent’s in vivo delivery platform will have significant clinical benefit."

Peter Parker, President and CEO at Cequent, said: "Cobra has an excellent track record of developing innovative solutions for molecular biology and biologic therapy, and we look forward to collaborating with Cobra's outstanding scientific team to evaluate their ORT technology for use in our therapeutic tkRNAi bacteria.”

Advertisement